App-Quantinova.ai

EPICAL Trial. A Phase Ib StudyCombining Anti-Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR-Mutant Non-Small Cell Lung Cancer

D. Rodriguez Abreu - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Non Small Cell Lung cancer

Afatinib

Patients’ Experiences During COVID-19: Insights from The Second Global Lung Cancer Coalition Patient Experience Survey

J. Fenemore - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Lung Cancer

N/A

Considering the Continued Impact of the COVID-19 Pandemic on Patient Advocacy and Support Organisations

M. Peters - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Lung Cancer

N/A

Impact of Heart and Lung Radiation Dose and Lymphopenia on Non-Small Cell Lung Cancer Outcomes

J. Little - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Deep Learning-Based Survival Prediction for Non-Small Cell Lung Cancer Patients Undergoing Radical Radiotherapy

J. Astley - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy

A. Lee - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults

B. Leung - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Immunotherapy in Lung Cancer: Analysis of Patients’ Awareness and Perceptions

P. Kosmidis - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

FP 02.2

DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

P. Forde - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Malignant pleural mesothelioma

Durvalumab

Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy

T. Mitchell - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

M.R. Garc�a Campelo - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

L-Tyrosine

Obesity is Associated With Greater Overall Survival in Patients With Metastatic NSCLC Receiving First-Line Pembrolizumab

F. Thomson - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Pembrolizumab

Retrospective Study on the Correlation of Central Tumour and Central Structures and the Effect on Survival for Patients Receiving Lung SABR

N.A. Mokhtar - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Building Personalized Follow-Up Care Through AI by Bringing the Lung Cancer Patient, Data Scientist and Oncologist Together

M. Torrente - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Lorlatinib in First Line Treatment of Patients With ALK-Positive NSCLC: A Network Meta-Analysis

J. Gregory - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

brigatinib

Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors

L. Bazhenova - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

L-Tyrosine

Patient Behaviors and Attitudes Towards Lung Cancer Medication Adherence

P. Kosmidis - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Trends in Treatment Patterns and Survival in Advanced NSCLC Patients Treated at Frankfurt University Hospital in 2012–2018

A. Wolf - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital

S. Shaid - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Nivolumab

Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC

M.D. Hellmann - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Filters

45280 Abstracts